Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Invested Capital (2016 - 2025)

ImmunityBio (IBRX) has disclosed Invested Capital for 12 consecutive years, with -$500.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital fell 65.39% to -$500.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$500.5 million, a 65.39% decrease, with the full-year FY2025 number at -$500.5 million, down 65.39% from a year prior.
  • Invested Capital was -$500.5 million for Q4 2025 at ImmunityBio, up from -$523.4 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $85.5 million in Q1 2025 to a low of -$724.5 million in Q3 2024.
  • A 5-year average of -$398.1 million and a median of -$425.5 million in 2022 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: crashed 2915.16% in 2023, then soared 112.38% in 2025.
  • ImmunityBio's Invested Capital stood at -$243.9 million in 2021, then skyrocketed by 92.65% to -$17.9 million in 2022, then plummeted by 2915.16% to -$540.3 million in 2023, then soared by 43.99% to -$302.6 million in 2024, then tumbled by 65.39% to -$500.5 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Invested Capital are -$500.5 million (Q4 2025), -$523.4 million (Q3 2025), and -$569.8 million (Q2 2025).